Ahmed U. Ali
Ahmed U. Ali has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Amira A. Kamel
Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Assiut University, Assiut, Egypt
3 shared publicationsTahani H. El Faham
Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt
2 shared publications- Abeer Saad Hassan
Department of Pharmaceutics, Faculty of Pharmacy, South Valley University, Qena, Egypt
1 shared publication Ahmed Haredy
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Merit University, New Sohag, Egypt
1 shared publication- Ahmed Mohammed Abd-Eldayem
Department of Medical Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt
1 shared publication Ahmed Mortada
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Egyptian Knowledge Bank in Merit Medical Journal
- Vol. 1 (1) , 21-27
Porous microparticles as a tool for minimizing 5-Fluorouracil induced intestinal mucositis.
5 Fluorouracil (5-FU) is used primarily to treat solid malignant tumors and is administered via the intravenous route; however, this administration is accompanied by intestinal mucositis, represented by diarrhea. In this work, 5-FU microsponges (porous microparticles) were prepared to be taken orally to minimize the intestinal mucositis associated with the intravenous IV administration of 5-FU. 15 male albino rabbits were utilized to compare the degree of intestinal mucositis related to the intravenous administration to that of 5-FU microsponges capsule oral administration (at the same dose). The experiment was conducted for five consecutive days. Results showed that the mean villus height of the IV group measured about 260.0± 6.9 µm, which was considerably lower (p<0.05) than that of the Capsule group, which measured about 285.0± 9.3 µm; in addition, the mean depth of crypts of IV group measured about 110.0± 6.8 µm which is significant (p<0.05) lower than that of Capsule group which measured about 141.0± 7.8 µm which means that the degree of intestinal mucositis induced by the intravenous injection of 5-FU was significantly higher than that caused by that of oral administration of 5- FU microsponges formulation. By the way, on the fourth day, one rabbit of the IV group died, indicating the severity of the intestinal mucositis after the IV administration of 5-FU. The results showed that the oral administration of 5-FU microsponges is more safe than IV drug administration at the same dose.
- 1 January 2024
- Published by Egyptian Knowledge Bank in Merit Medical Journal
- Vol. 1 (1) , 21-27
Open AccessPorous microparticles as a tool for minimizing 5-Fluorouracil induced intestinal mucositis.
5 Fluorouracil (5-FU) is used primarily to treat solid malignant tumors and is administered via the intravenous route; however, this administration is accompanied by intestinal mucositis, represented by diarrhea. In this work, 5-FU microsponges (porous microparticles) were prepared to be taken orally to minimize the intestinal mucositis associated with the intravenous IV administration of 5-FU. 15 male albino rabbits were utilized to compare the degree of intestinal mucositis related to the intravenous administration to that of 5-FU microsponges capsule oral administration (at the same dose). The experiment was conducted for five consecutive days. Results showed that the mean villus height of the IV group measured about 260.0± 6.9 µm, which was considerably lower (p<0.05) than that of the Capsule group, which measured about 285.0± 9.3 µm; in addition, the mean depth of crypts of IV group measured about 110.0± 6.8 µm which is significant (p<0.05) lower than that of Capsule group which measured about 141.0± 7.8 µm which means that the degree of intestinal mucositis induced by the intravenous injection of 5-FU was significantly higher than that caused by that of oral administration of 5- FU microsponges formulation. By the way, on the fourth day, one rabbit of the IV group died, indicating the severity of the intestinal mucositis after the IV administration of 5-FU. The results showed that the oral administration of 5-FU microsponges is more safe than IV drug administration at the same dose.
- 7 October 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 90
Serum levels of tumor necrosis factor (TNF-α) and vaginal gene expression of toll-like receptor 2 (TLR2) & microtubule-associated protein 1 light chain 3 (LC3) after treatment of vulvovaginal candidiasis with sertaconazole nitrate spanlastics
- 7 October 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 90
Serum levels of tumor necrosis factor (TNF-α) and vaginal gene expression of toll-like receptor 2 (TLR2) & microtubule-associated protein 1 light chain 3 (LC3) after treatment of vulvovaginal candidiasis with sertaconazole nitrate spanlastics
- Open Access
- 8 April 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-14
Impact of porous microsponges in minimizing myotoxic side effects of simvastatin
Simvastatin (SV) is a poorly soluble drug; its oral administration is associated with a significant problem: Myopathy. The present study aims to formulate SV microsponges that have the potential to minimize the myotoxicity accompanying the oral administration of the drug. SV microsponges were prepared by exploiting the emulsion solvent evaporation technique. The % entrapment efficiency (%EE) of the drug approached 82.54 ± 1.27%, the mean particle size of SV microsponges ranged from 53.80 ± 6.35 to 86.03 ± 4.79 µm in diameter, and the % cumulative drug release (%CDR) of SV from microsponges was significantly higher than that from free drug dispersion much more, the specific surface area of the optimized microsponges formulation was found to be 16.6 m2/g revealed the porosity of prepared microsponges. Histological and glycogen histochemical studies in the skeletal muscles of male albino rats revealed that microsponges were safer than free SV in minimizing myotoxicity. These findings were proven by Gene expression of Mitochondrial fusion and fission (Mfn1) & (Fis1) and (Peroxisome proliferator-activated receptor gamma co-activator 1α) PGC-1α. Finally, our study ascertained that SV microsponges significantly decreased the myotoxicity of SV.
- 8 April 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-14
Open AccessImpact of porous microsponges in minimizing myotoxic side effects of simvastatin
Simvastatin (SV) is a poorly soluble drug; its oral administration is associated with a significant problem: Myopathy. The present study aims to formulate SV microsponges that have the potential to minimize the myotoxicity accompanying the oral administration of the drug. SV microsponges were prepared by exploiting the emulsion solvent evaporation technique. The % entrapment efficiency (%EE) of the drug approached 82.54 ± 1.27%, the mean particle size of SV microsponges ranged from 53.80 ± 6.35 to 86.03 ± 4.79 µm in diameter, and the % cumulative drug release (%CDR) of SV from microsponges was significantly higher than that from free drug dispersion much more, the specific surface area of the optimized microsponges formulation was found to be 16.6 m2/g revealed the porosity of prepared microsponges. Histological and glycogen histochemical studies in the skeletal muscles of male albino rats revealed that microsponges were safer than free SV in minimizing myotoxicity. These findings were proven by Gene expression of Mitochondrial fusion and fission (Mfn1) & (Fis1) and (Peroxisome proliferator-activated receptor gamma co-activator 1α) PGC-1α. Finally, our study ascertained that SV microsponges significantly decreased the myotoxicity of SV.
- 17 September 2022
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 76
Impact of quercetin spanlastics on livin and caspase-9 expression in the treatment of psoriasis vulgaris
- 17 September 2022
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 76
Impact of quercetin spanlastics on livin and caspase-9 expression in the treatment of psoriasis vulgaris
- 30 March 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , E373-E379
Efficacy of topical versus intradermal injection of Tranexamic Acid In Egyptian melasma Patients: A randomised clinical trial
Background: Melasma is one of the common pigmentary problems affecting females in our community, owing to the frequent use of hormonal contraceptives as well as our sunny climate. A lot of treatment options are available but none of them is completely satisfactory. Many patients prefer the use of topical preparations and minimally invasive methods. Tranexamic acid (TA) is a potential treatment option for hyperpigmentation with different delivery routes.Aim: We designed the study in order to evaluate the efficacy of TA in melasma using 2 different routes of delivery.Patients and methods: A randomised clinical trial was performed on 60 female patients with melasma, they randomly divided into three groups; A, B and C. Group (A) patients received TA (4 mg/mL) intradermal injections every 2 weeks with, group B received TA (10 mg/mL) intradermal injections every 2 weeks, group C received TA cream (10% concentration) twice daily, treatment continued for 12 weeks in all groups. Melasma Area and Severity Index (MASI) scores were measured for each patient before and after completion of treatment.Results: The percentage of MASI score reduction was highest in group B (62.7%) versus (39.1%) in group A, while the percentage of MASI reduction was the lowest in group C (4.2%).Conclusion: Tranexamic acid is a safe effective and well‐tolerated treatment option for melasma patients. Intradermal injection of TA leads to better results than the topical application. Topical TA cream (even in a high concentration) produce fair improvement of melasma.
- 30 March 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , E373-E379
Efficacy of topical versus intradermal injection of Tranexamic Acid In Egyptian melasma Patients: A randomised clinical trial
Background: Melasma is one of the common pigmentary problems affecting females in our community, owing to the frequent use of hormonal contraceptives as well as our sunny climate. A lot of treatment options are available but none of them is completely satisfactory. Many patients prefer the use of topical preparations and minimally invasive methods. Tranexamic acid (TA) is a potential treatment option for hyperpigmentation with different delivery routes.Aim: We designed the study in order to evaluate the efficacy of TA in melasma using 2 different routes of delivery.Patients and methods: A randomised clinical trial was performed on 60 female patients with melasma, they randomly divided into three groups; A, B and C. Group (A) patients received TA (4 mg/mL) intradermal injections every 2 weeks with, group B received TA (10 mg/mL) intradermal injections every 2 weeks, group C received TA cream (10% concentration) twice daily, treatment continued for 12 weeks in all groups. Melasma Area and Severity Index (MASI) scores were measured for each patient before and after completion of treatment.Results: The percentage of MASI score reduction was highest in group B (62.7%) versus (39.1%) in group A, while the percentage of MASI reduction was the lowest in group C (4.2%).Conclusion: Tranexamic acid is a safe effective and well‐tolerated treatment option for melasma patients. Intradermal injection of TA leads to better results than the topical application. Topical TA cream (even in a high concentration) produce fair improvement of melasma.